Repository logo
 
Publication

Systematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescents

2022-12Journal article Open access
Simple item page
dc.contributor.authorSantos, Josiane M.
dc.contributor.authorFachi, Mariana M.
dc.contributor.authorBeraldi-Magalhães, Francisco
dc.contributor.authorBöger, Beatriz
dc.contributor.authorJunker, Allan M.
dc.contributor.authorDomingos, Eric L.
dc.contributor.authorImazu, Priscila
dc.contributor.authorFernandez-Llimos, Fernando
dc.contributor.authorTonin, Fernanda
dc.contributor.authorPontarolo, Roberto
dc.date.accessioned2022-09-08T13:49:53Z
dc.date.available2024-09-08T00:30:27Z
dc.date.issued2022-12
dc.description.abstractBackground: We aimed to synthesize the evidence on the efficacy and safety of different treatment regimens for latent tuberculosis infection (LTBI) in children and adolescents. Methods: A systematic review with network meta-analysis was performed (CRD142933). Searches were conducted in Pubmed and Scopus (Nov-2021). Randomized controlled trials comparing treatments for LTBI (patients up to 15 years), and reporting data on the incidence of the disease, death, or adverse events were included. Networks using the Bayesian framework were built for each outcome of interest. Results were reported as odds ratio (OR) with 95% credibility intervals (CrI). Rank probabilities were calculated via the surface under the cumulative ranking analysis (SUCRA) (Addis-v.1.16.8). GRADE approach was used to rate evidence's certainty. Results: Seven trials (n = 8696 patients) were included. Placebo was significantly associated with a higher incidence of tuberculosis compared to all active therapies. Combinations of isoniazid (15–25 mg/kg/week) plus rifapentine (300–900 mg/week), followed by isoniazid plus rifampicin (10 mg/kg/day) were ranked as best approaches with lower probabilities of disease incidence (10% and 19.5%, respectively in SUCRA) and death (20%). Higher doses of isoniazid monotherapy were significantly associated with more deaths (OR 18.28, 95% ICr [1.02, 48.60] of 4–6 mg/kg/day vs. 10 mg/kg/3x per week). Conclusions: Combined therapies of isoniazid plus rifapentine or rifampicin for short-term periods should be used as the first-line approach for treating LTBI in children and adolescents. The use of long-term isoniazid as monotherapy and at higher doses should be avoided for this population.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationSantos JM, Fachi MM, Beraldi-Magalhães F, Böger B, Junker AM, Tonin FS, et al. Systematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescents. J Infect Chemother. 2022;28(12):1645-53.pt_PT
dc.identifier.doi10.1016/j.jiac.2022.08.023pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/14953
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S1341321X22002495pt_PT
dc.subjectTuberculosispt_PT
dc.subjectAntitubercular agentspt_PT
dc.subjectInfantpt_PT
dc.subjectSystematic reviewpt_PT
dc.subjectNetwork meta-analysispt_PT
dc.titleSystematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescentspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage1653pt_PT
oaire.citation.issue12pt_PT
oaire.citation.startPage1645pt_PT
oaire.citation.titleJournal of Infection and Chemotherapypt_PT
oaire.citation.volume28pt_PT
person.familyNameTonin
person.givenNameFernanda
person.identifier.ciencia-idD01C-C700-9411
person.identifier.orcid0000-0003-4262-8608
person.identifier.ridO-2050-2017
person.identifier.scopus-author-id56085115800
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication61ded30e-ecec-4b3e-b953-2293e080ebdd
relation.isAuthorOfPublication.latestForDiscovery61ded30e-ecec-4b3e-b953-2293e080ebdd

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Systematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescents.pdf
Size:
2.88 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos